KYTX at a glance
Kyverna Therapeutics Inc (KYTX, SEC CIK 1994702) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as May 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Kyverna Therapeutics Inc (KYTX) shares worth $110.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $110.4M · +3 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New legal risk: securities class action survived dismissal of Sections 11 and 15 claims on October 20, 2026
- Regulatory risk: FDA CAR-T malignancy investigation could require boxed warnings, lifetime monitoring, or added post-approval obligations
- Operational risk: miv-cel BLA submitted in fourth quarter 2026, but FDA acceptance and approval remain uncertain
- Financial risk: $120.0 million nine-month net loss and $544.8 million accumulated deficit require substantial additional capital
- Competitive risk: miv-cel faces approved therapies including Rituxan and Ocrevus plus emerging CAR-T and T-cell engager treatments
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no approved products or product sales
- Net loss $41.9M vs $36.8M YoY, operating loss $42.9M vs $38.7M
- R&D $27.0M, down 11%; G&A $15.9M, up 92%, worst cost trend
- Cash, equivalents and marketable securities $170.6M; nine-month operating cash use $117.3M
- SPS BLA completed in fourth quarter 2026, potential 2027 launch; funding expected for at least 12 months
AI summary of the KYTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and business update released for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for operating metrics, cash position and pipeline developments
Item EX-99.1: Item EX-99.1
- BLA submission completed for miv-cel in stiff person syndrome, with FDA priority review requested
- Potential 2027 launch would target the first approved SPS therapy and autoimmune CAR-T, creating significant commercial upside if approved
Item 7.01: Regulation FD Disclosure
- Positive one-year KYSA-8 data for miv-cel in stiff person syndrome, supporting registrational development
- Positive longer-term Phase 2 KYSA-6 follow-up in generalized myasthenia gravis, strengthening durability evidence
Item EX-99.1: Item EX-99.1
- SPS 12-month data: 49% median T25FW improvement, with 95% sustaining clinically meaningful benefit
- 67% of pre-treatment walking-aid users remained independent, supporting meaningful reversal of disability
Item 2.02: Results of Operations and Financial Condition
- Kyverna reported financial results for the quarter ended June 30, 2026
- Business update and quarterly results available in Exhibit 99.1, relevant for pipeline and liquidity assessment
Item EX-99.1: Item EX-99.1
- RMAT designation for miv-cel in non-active SPMS expands regulatory pathways and supports a broader neuroimmunology franchise
- Rolling SPS BLA submission on track for Q4 2026, with potential priority review and 2027 commercial launch
AI summaries of KYTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KYTX
Don't miss the next KYTX filing
- Alerts as it files. A push when KYTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KYTX, by share count.
- Ask anything. An AI agent that reads every KYTX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shaw Christi | F | May 27, 2026 | 4,194 | $8.59 |
| CLARK IAN T | A | May 27, 2026 | 20,582 | - |
| SEIDENBERG BETH C | A | May 27, 2026 | 5,093 | - |
| SEIDENBERG BETH C | A | May 27, 2026 | 20,582 | - |
| Cohen Fred E | A | May 27, 2026 | 5,093 | - |
| Cohen Fred E | A | May 27, 2026 | 20,582 | - |
| Aktar Mert | A | May 27, 2026 | 5,093 | - |
| Aktar Mert | A | May 27, 2026 | 20,582 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$62.4M | -$142.6M | -$169.8M |
| Net Income | - | -$127.5M | -$161.3M |
| Balance Sheet | |||
| Total Assets | $75.2M | $304.6M | $293.8M |
| Equity | -$131.4M | $266.6M | $232.3M |
| ROE | - | -47.8% | -69.4% |
| Per Share | |||
| EPS | $-89.61 | $-3.33 | $-3.64 |
| Cash Flow | |||
| Operating CF | -$52.4M | -$114.3M | -$153.7M |
| CapEx | $621K | $2.2M | $5K |
Source: XBRL data in Kyverna Therapeutics Inc (KYTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate KYTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $110.4M |
| Q2 2026 | 23 | $141.7M |
| Q1 2026 | 23 | $108.9M |
| Q4 2025 | 21 | $108.8M |
| Q3 2025 | 21 | $57.3M |
| Q2 2025 | 21 | $31.4M |
| Q1 2025 | 19 | $16.6M |
| Q4 2024 | 15 | $31.0M |
- State Street Corp+221.0K (+23%)
- Goldman Sachs Group+216.7K (+65%)
- Dimensional Fund Advisors+200.1K (+255%)
- Millennium Management+186.4K (+29%)
- Vanguard Capital Management LLC+113.7K (+6%)
- Morgan Stanley−430.1K (-44%)
- D.E. Shaw & Co−322.5K (-69%)
- Bank of America Corp−220.4K (-83%)
- Two Sigma Investments−29.7K (-58%)
- Citigroup−17.2K (-82%)
- Raymond James Financial+129.0K
- Franklin Resources+78.0K
- AQR Capital Management+16.4K
- U.S. Bancorp+119
- FMR LLC (Fidelity)−96.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KYTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 8-K | Jun 2, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 18, 2026 | - | - | |
| 8-K | May 12, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | - | |
| 4 | May 6, 2026 | - | - | |
| 8-K | May 4, 2026 | - | - | - |
| 8-K | Apr 22, 2026 | - | - | - |
| 8-K | Apr 22, 2026 | - | - | - |
| 8-K | Apr 20, 2026 | - | - | - |
| 8-K | Mar 26, 2026 | - | - | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - | |
| 4 | Mar 17, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
KYTX SEC filings: frequently asked questions
Which institutions hold KYTX stock?
As of September 30, 2026, the largest Kyverna Therapeutics Inc (KYTX) holders among the 13F filers tracked by SignalX were Gilead Sciences ($28.1 million), BlackRock ($22.0 million), Vanguard Capital Management LLC ($13.7 million), T. Rowe Price Group ($8.2 million), State Street Corp ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did KYTX report in its latest 8-K?
Kyverna Therapeutics Inc (KYTX) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and business update released for quarter ended September 30, 2026.
What are the latest KYTX SEC filings?
Kyverna Therapeutics Inc (KYTX) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on May 29, 2026.
What is KYTX's SEC CIK number?
Kyverna Therapeutics Inc (KYTX)'s SEC Central Index Key (CIK) is 1994702. EDGAR lists every KYTX filing under that number.
Ask anything about KYTX
The research agent reads KYTX's filings, financials, insider trades and 13F holders, then answers with sources.